实用癌症杂志
實用癌癥雜誌
실용암증잡지
The Practical Journal of Cancer
2015年
8期
1257-1260
,共4页
骨髓增生异常综合征%高危%老年%HAG预激
骨髓增生異常綜閤徵%高危%老年%HAG預激
골수증생이상종합정%고위%노년%HAG예격
Myelodysplastic syndrome( MDS)%High-risk%Elderly%HAG regimen
目的 探讨HAG预激方案治疗老年高危骨髓增生异常综合征( MDS)患者的疗效. 方法 高危MDS患者24例,随机分为HAG组和对照组,每组12例. HAG组采用HAG预激方案治疗,对照组采用标准化疗方案治疗. 化疗前后监测血常规、肝肾功能、心电图、骨髓等变化,统计疗效和不良反应. 结果 性别、体质量( BMI)、年龄、经济收入、婚姻状况、应激状态、高血压、职业、是否吸烟、是否饮酒、民族、糖尿病史、冠心病史、WHO分型和乳酸脱氢酶均与HAG预激方案疗效无关(P>0.05). 多因素分析显示性别、WHO分型和乳酸脱氢酶均与HAG预激方案疗效无关(P>0.05).HAG组不良反应较轻. 结论 HAG预激方案治疗老年高危MDS患者,疗效显著,不良反应较轻,安全性高,适用于老年高危MDS患者.
目的 探討HAG預激方案治療老年高危骨髓增生異常綜閤徵( MDS)患者的療效. 方法 高危MDS患者24例,隨機分為HAG組和對照組,每組12例. HAG組採用HAG預激方案治療,對照組採用標準化療方案治療. 化療前後鑑測血常規、肝腎功能、心電圖、骨髓等變化,統計療效和不良反應. 結果 性彆、體質量( BMI)、年齡、經濟收入、婚姻狀況、應激狀態、高血壓、職業、是否吸煙、是否飲酒、民族、糖尿病史、冠心病史、WHO分型和乳痠脫氫酶均與HAG預激方案療效無關(P>0.05). 多因素分析顯示性彆、WHO分型和乳痠脫氫酶均與HAG預激方案療效無關(P>0.05).HAG組不良反應較輕. 結論 HAG預激方案治療老年高危MDS患者,療效顯著,不良反應較輕,安全性高,適用于老年高危MDS患者.
목적 탐토HAG예격방안치료노년고위골수증생이상종합정( MDS)환자적료효. 방법 고위MDS환자24례,수궤분위HAG조화대조조,매조12례. HAG조채용HAG예격방안치료,대조조채용표준화료방안치료. 화료전후감측혈상규、간신공능、심전도、골수등변화,통계료효화불량반응. 결과 성별、체질량( BMI)、년령、경제수입、혼인상황、응격상태、고혈압、직업、시부흡연、시부음주、민족、당뇨병사、관심병사、WHO분형화유산탈경매균여HAG예격방안료효무관(P>0.05). 다인소분석현시성별、WHO분형화유산탈경매균여HAG예격방안료효무관(P>0.05).HAG조불량반응교경. 결론 HAG예격방안치료노년고위MDS환자,료효현저,불량반응교경,안전성고,괄용우노년고위MDS환자.
Objective To investigate the curative effect of HAG regimen for elderly patients with high-risk myelodys-plastic syndrome ( MDS) .Methods 24 cases of elderly patients with high-risk MDS were randomly divided into the HAG group and the control group,with 12 cases in each.The HAG group received HAG regimen,and the control group received standard chemotherapy.Changes of blood routine,liver and rental function,electrocardiogram,and marrow were collected.Curative effect and adverse reactions were recorded.Results Gender,BMI,age,smoking,drinking WHO classification and LDH was not correla-ted with efficacy of HAG (P>0.05).Multiple factors showed that Gender,WHO classification and LDH was not correlated with curative effect of HAG (P>0.05).Adverse effect of HAG group was lighter.Conclusion HAG regimen on the elderly patients with high-risk myelodysplastic syndrome has significant effect,light adverse effect,high safety,and is suitable for elderly patients with high-risk myelodysplastic syndrome.